Sobi Raises 2026 Outlook as Q3 Revenue Climbs 16% to SEK 9.1B
STOCKHOLM – October 27, 2026 -- Sobi raised its 2026 revenue growth guidance to high-teens to low-20s per cent at constant exchange rates (CER), up from mid- to high-teens, after third-quarter revenue grew 16 per cent at CER to SEK 9,124 M (7,776). Reported growth was 17 per cent, and year-to-date growth stands at 23 per cent at CER. The company also announced that CEO Guido Oelkers will step down no later than the end of January 2027.
Haematology revenue rises 29% as Altuvoct sales more than double
Haematology revenue increased 29 per cent at CER to SEK 6,171 M (4,771). Altuvoct sales reached SEK 1,729 M, up from SEK 769 M a year earlier. Doptelet added SEK 1,829 M (1,408).
Revenue from Sobi's strategic portfolio grew 25 per cent at CER to SEK 6,298 M (5,001).